Pharmafile Logo
Pharmafocus logo
Advanced Search

multiple myeloma

Showing 15 posts of 81 posts found.

europe-1395916_640

Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment

July 30, 2025
Medical Communications, Research and Development European Commission, Oncology, Sanofi, Sarclisa, european union, multiple myeloma

Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and …

News
blood_test

CHMP issues positive opinion for Blenrep combinations in relapsed/refractory multiple myeloma

May 23, 2025
Market & Product Development, Medical Communications, Research and Development Blenrep, Committee for Medicinal Products for Human USE, European Medicines Agency, Oncology, multiple myeloma

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion …

News

Multiple myeloma treatment approved in Japan

May 21, 2025
Market Access, Research and Development, Sales and Marketing GSK, Japan, Oncology, Orphan Drug Designation (ODD), multiple myeloma

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and Welfare for the treatment of …

News

MHRA approve new treatment combo for transplant-ineligible multiple myeloma patients

January 30, 2025
Research and Development MHRA, Oncology, approvals, multiple myeloma, rare diseases

The Medicine and Healthcare products Regulatory Agency (MHRA) has approved quadruplet therapy, SARCLISA (isatuximab) in combination to treat multiple myeloma …

News

AbbVie initiates phase 3 multiple myeloma trial

June 6, 2024
Medical Communications ABBV-383, AbbVie, Oncology, clinical trial, multiple myeloma

AbbVie has announced that it has dosed the first patient in its phase 3 CERVINO trial, which aims to assess …

News
testalize-me-0je8ynv4mis-unsplash

Sanofi shares phase 3 trial results for Sarclisa in multiple myeloma treatment

June 5, 2024
Research and Development Oncology, Sanofi, Sarclisa, clinical trial, multiple myeloma

Sanofi has announced data from the IMROZ phase 3 trial which assessed Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide …

News

Sanofi’s Sarclisa accepted for FDA priority review

May 29, 2024
Medical Communications FDA, Oncology, Sanofim, Sarclisa, multiple myeloma, priority review

Sanofi has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …

News

Heidelberg Pharma gains FDA ODD for ATAC candidate

March 27, 2024
Research and Development FDA, Oncology, heidelberg pharma, multiple myeloma

Heidelberg Pharma has announced that it has gained Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) …

News

GSK shares results from phase 3 trial for Blenrep for treatment of multiple myeloma

March 7, 2024
Research and Development Blenrep, GSK, Oncology, clinical trial, multiple myeloma

GSK has announced positive results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial which assesses Blenrep (belantamab …

News

Regeneron’s linvoseltamab gains EMA filing acceptance for R/R MM treatment

February 5, 2024
Medical Communications EMA, Oncology, Regeneron, linvoseltamab, multiple myeloma

Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorisation Application (MAA) for …

News

FDA clears IND for Gracell Biotechnologies’ phase 1 clinical trial for multiple myeloma treatment

January 30, 2024
Research and Development FDA, Gracell Biotechnologies, Oncology, clinical trial, multiple myeloma

Gracell Biotechnologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, …

News

EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma

December 12, 2023
Medical Communications Elrexfio, European Commission, Oncology, Pfizer, multiple myeloma

Pfizer has announced that the European Commission (EC) has granted conditional marketing authorisation for Elrexfio (elranatamab) for the treatment of …

News
testalize-me-0je8ynv4mis-unsplash

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023
Medical Communications Blenrep, GSK, Oncology, clinical trial, multiple myeloma

GSK has announced positive results from a planned interim efficacy analysis of the phase 3 DREAMM-7 head-to-head trial which assessed …

News
hal-gatewood-_jbclosdsd4-unsplash

FDA grants ODD to NXC-201 as multiple myeloma treatment

August 24, 2023
Medical Communications FDA, Nexcella, ODD, Oncology, multiple myeloma

Nexcella has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NXC-201 for …

News
pawel-czerwinski-2y8ol_obs1i-unsplash_2

FDA approves Talvey for the treatment of heavily pretreated multiple myeloma

August 11, 2023
Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma

The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has granted …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026